Anti-Her2 / ERBB2 Antibody

Epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD34, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.

• Cancer Immunotherapy
• Immune Checkpoint
• Immunotherapy
• Targeted Therapy

erb-b2 receptor tyrosine kinase 2

• Cancer>>Cancer Types>>Breast Cancer
• Cancer>>Cancer Biomarker
• Immunology>>Inflammation / Inflammatory Mediator>>Inflammatory Cytokines & Chemoki and Receptors>>EGF Family
• Cardiovascular>>Angiogenesis>>Growth Factor & Receptor>>Epidermal Growth Factor (EGF) & Receptor>>EGF Receptor
• Stem Cells>>Neural Stem Cells (NSCs)>>Mesenchymal Stem Cell (MSC) Marker
• Immunology>>Cluster of Differentiation (CD)>>Other CD Antigen
• Cardiovascular>>Angiogenesis>>Growth Factor & Receptor>>Receptor Tyrosine Kinase (RTK)
• Cancer>>Signal Transduction>>Protein Phosphorylation>>Tyrosine Kinase>>Receptor Tyrosine Kinases
• Cancer>>Signal Transduction>>Receptor Tyrosine Kinases (RTKs)
• Cancer>>Signal Transduction>>Akt Pathway>>Receptor Tyrosine Kinases (RTKs) in the Akt Pathway
• Cancer>>Signal Transduction>>Jak/STAT Signaling>>Receptors in the Jak/STAT Pathway
• Cancer>>Cancer immunology>>Tumor-associated antigen

• Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.